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Abstract 
Background: Vascular dysfunction is a pivotal event in the development of diabetes-associated vascular disease. 
Increased inflammation and oxidative stress are major contributors to vascular dysfunction. Nrf2, a master regulator 
of several anti-oxidant genes and a suppressor of inflammatory NF-κB, has potential as a target to combat oxidative 
stress and inflammation. The aim of this study was to investigate the effects of a novel Nrf2 activator, the bardoxolone 
methyl derivative dh404, on endothelial function in vitro and in vivo.
Methods: dh404 at 3 mg/kg was administered to male Akita mice, an established diabetic mouse model of insulin 
insufficiency and hyperglycemia, from 6 weeks of age. At 26 weeks of age, vascular reactivity was assessed by wire 
myography, pro-inflammatory expression was assessed in the aortas by qRT-PCR and immunohistochemistry, and sys-
temic and vascular oxidative stress measurements were determined. Additionally, studies in human aortic endothelial 
cells (HAECs) derived from normal and diabetic patients in the presence or absence of dh404 included assessment 
of pro-inflammatory genes by qRT-PCR and western blotting. Oxidative stress was assessed by three methods; L-012, 
DCFDA and amplex red. Static adhesion assays were performed to determine the leukocyte–endothelial interaction in 
the presence or absence of dh404.
Results: Dh404 significantly attenuated endothelial dysfunction in diabetic Akita mice characterized by reduced 
contraction in response to phenylephrine and the downregulation of inflammatory genes (VCAM-1, ICAM-1, p65, 
IL-1β) and pro-oxidant genes (Nox1 and Nox2). Furthermore, reduced systemic and vascular oxidative stress levels 
were observed in diabetic Akita mice. dh404 exhibited cytoprotective effects in diabetic HAECs in vitro, reflected by 
significant upregulation of Nrf2-responsive genes, NAD(P)H quinone oxidoreductase 1 (NQO1) and heme oxyge-
nase-1 (HO-1), reduction of oxidative stress markers (O2
·− and H2O2), inhibition of inflammatory genes (VCAM-1 and 
the p65 subunit of NF-κB) and attenuation of leukocyte–endothelial interactions (P < 0.05 for all in vitro and in vivo 
parameters; one or two-way ANOVA as appropriate with post hoc testing).
Conclusion: These studies demonstrate that upregulation of Nrf2 by dh404 represents a novel therapeutic strategy 
to limit diabetes-associated vascular injury.
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Background
A consistent phenomenon in diabetic patients is the 
development of endothelial dysfunction, which precedes 
the development of diabetes-associated vascular com-
plications. Diabetic-endothelial dysfunction is charac-
terized by enhanced vascular contractility, increased 
oxidative stress and vascular inflammation, in particu-
lar adhesion of inflammatory cells to the vascular wall 
[1–3]. Hyperglycemia-induced oxidative stress plays a 
critical role in accelerating processes that contribute to 
endothelial dysfunction. For example, elevated oxidative 
stress has been shown to reduce the bioavailability of the 
potent endothelial mediator, nitric oxide, resulting in vas-
cular impairment [4]. In addition, oxidative stress directly 
elevates the expression of pro-inflammatory and adhe-
sion molecules, facilitating the recruitment and infiltra-
tion of leukocytes/monocytes into the vasculature [5–7]. 
Despite the unequivocal evidence that supports the role 
of oxidative stress in diabetes-associated vascular com-
plications, strategies to combat oxidative stress using tra-
ditional antioxidants have proved inconclusive in large 
clinical trials with respect to cardiovascular end-points 
[8]. Thus, current research is focused on mechanism-
based antioxidants that offer a more targeted approach to 
ameliorate oxidative stress.
One such strategy that has gained considerable atten-
tion is the NF-E2-related factor 2 (Nrf2) pathway. Nrf2 
is a ubiquitously expressed redox sensitive transcription 
factor that is kept in a latent state through its interaction 
with its repressor protein, Kelch ECH associating protein 
1 (Keap-1). In response to increased free radicals, the 
Keap protein is oxidized or covalently modified releas-
ing Nrf2, which then enters the nucleus and binds to the 
antioxidant response element (ARE), thereby initiating 
the transcription of a host of antioxidant genes, includ-
ing superoxide dismutase (SOD), catalase, heme-oxyge-
nase 1 (HO-1) and NAD(P)H:Quinone Oxidoreductase 
1 (NQO1) [9–13]. Additionally, Nrf2 has demonstrated 
anti-inflammatory properties driven through its ability 
to negatively regulate nuclear factor-kappaB (NF-kB), the 
transcription factor central to the inflammatory response 
[14].
Numerous chemically diverse activators of the Nrf-2/
Keap-1 pathways have been identified, including the 
natural compounds sulforaphane from cruciferous veg-
etables and cinnamic aldehyde found in cinnamon bark 
[13–15]. Synthetic small molecule activators of the Nrf2/
Keap1 pathway include bardoxolone methyl (BM), which 
belongs to the antioxidant inflammation modulator 
(AIM) drug class [16–18]. BM has shown structural and 
functional improvements in rodent models of renal dis-
ease [19, 20], and its therapeutic potential was extended 
to clinical trials in type 2 diabetic patients with chronic 
kidney disease in which improvements in estimated 
glomerular filtration rate (eGFR) were observed, but 
with limitations, mainly concerned with patient selec-
tion, due to fluid overload complications [21–24]. Fol-
low up analysis of the terminated BEACON trial has 
revealed important risk factors that need to be taken 
into account to avoid fluid overload and heart failure, 
including patients with elevated measures of baseline 
brain natriuretic peptide, a marker for fluid overload, and 
prior hospitalization for heart failure [25]. In a recently 
published study by our group, we demonstrated that a 
BM tool compound, dh404, attenuated atherosclerosis 
in diabetic Apolipoprotein E knockout (ApoE KO) mice 
in an inverse dose-dependent manner with lower doses 
being atheroprotective, highlighting the importance of 
careful dosage considerations for Nrf2 activators. Impor-
tantly, the antioxidant and anti-inflammatory properties 
of dh404 correlated with the observed improvements in 
diabetes-associated atherosclerosis [26]. Since endothe-
lial dysfunction, which is the critical first step to the 
development of vascular complications, is accompanied 
by pro-oxidative and pro-inflammatory conditions, we 
hypothesized that dh404 might be exerting its athero-
protective effects via improvements in endothelial dys-
function in the diabetic setting. This aspect has not been 
studied previously and warrants further attention.
In the current study, we investigated the effects of the 
Nrf2 activator, dh404, on endothelial function in the 
Akita mouse, a model of hyperglycemia and hypoinsu-
linemia due to improper folding of proinsulin [27] and 
in cultured aortic endothelial cells isolated from dia-
betic patients. We show that Nrf2 activation via dh404 
improves vascular function, by targeting pro-oxidative 
and pro-inflammatory pathways. As such, we propose 
that recovery of endothelial function, lost due to diabe-
tes, leads to vascular protection, and limits diabetes-
associated atherosclerosis.
Methods
Animal groups and experimental design
All animal experiments were approved by the Alfred 
Medical Research and Education Precinct (AMREP) 
animal ethics committee and investigations conformed 
to National Health and Medical Research Council 
(NHMRC; Australia) guidelines. Diabetic Akita mice 
(C57BL/6J-Ins2Akita) and their wild type (WT) coun-
terparts were purchased from the Jackson Laboratory 
(Sacramento, CA, USA) and bred at the AMREP Precinct 
Animal Centre. At 6 weeks of age, male mice of both gen-
otypes were randomly assigned to receive either vehicle 
(sesame oil), or dh404 (3 mg/kg) by daily oral gavage. As 
previously reported [26], this dose of dh404 is optimal 
in reducing diabetes-associated atherosclerosis. Blood 
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glucose and body weights were recorded on a weekly 
basis as part of animal monitoring.
Blood sampling, plasma biochemistry and tissue collection
At 26 weeks of age, mice were fasted for 3 h before ter-
mination for organ collection. Mice were anesthetized 
by injecting 2,2,2-Tribromoethanol (Avertin®; Sigma-
Aldrich, St. Louis, MO, USA) intraperitoneally. Follow-
ing which, the thoracic cavity was incised and blood was 
collected via direct puncture of the right ventricle. The 
blood was placed in heparinized tubes and centrifuged 
(room temperature for 10  min at 4000  rpm) to obtain 
plasma samples. Plasma glucose, cholesterol, HDL and 
triglycerides were measured as described previously 
[28].
The heart and aorta were dissected and placed in 
Krebs buffer (components in mM; NaCl 119, KCl 4.7, 
NaHCO3 25, MgSO4·7H20 1.17, CaCl2 2.5, KH2PO4 
1.18, glucose 11 and EDTA 0.03). The aorta was cleaned 
to remove peripheral fat under a dissecting micro-
scope and cut into two sections. The thoracic aorta was 
mounted on a wire myograph for vascular reactivity 
analysis while the arch and abdominal aorta was snap 
frozen in liquid nitrogen for RNA extraction. A portion 
of the thoracic aortas was frozen in OCT for immuno-
histochemical analysis.
Vascular reactivity
Vascular reactivity studies were performed as per Vais-
man et  al. [29]. Briefly, the thoracic aorta was cut into 
4  mm segments and mounted on two L-shaped metal 
prongs. One prong was linked to a force–displacement 
transducer for continuous recording of isometric tension 
by the LabChart software, while the other prong was con-
nected to a displacement device, which allowed adjust-
ment of the distance between the two parallel prongs. 
Aortas were then equilibrated for 30 min and normalised 
at resting tension (0  mN), 15 and 25  mN to obtain the 
final micrometer setting between the prongs.
Thereafter, aortas were exposed to an oxygenated and 
pre-warmed high potassium physiological salt solu-
tion (KPSS at 37  °C; components in mM; KCl 123, 
MgSO4·7H20 1.17, NaHCO3 25, KH2PO4 1.18, CaCl2 
2.5, glucose 6.05 and EDTA 0.03) to determine the via-
bility of the aortas. A dose–response to phenylephrine 
(PE) (1  nM–100  µM) was performed to assess vascu-
lar contractility and l-NG-Nitroarginine Methyl Ester 
(l-NAME; 100 μM)-induced contraction was assessed in 
aortas preconstricted to approximately 20% contraction 
of KPSS with u41699, an endothelium-independent vaso-
constrictor agent. The variable slope sigmoidal concen-
tration-responses curves to all agonists in each subject 
were calculated and plotted using GraphPad Prism (v6.0).
Aortic RNA extraction, gene expression 
and immunohistochemistry analysis
Aortas were snap frozen and total RNA was extracted 
after homogenization as described previously [26]. 
Probes and primers were purchased from Applied Bio-
systems (ABI, Foster City, CA, USA). Gene expression 
of vascular cell adhesion molecule (VCAM-1), intra-
cellular adhesion molecule (ICAM-1), nuclear factor 
(NF)-κB subunit p65, NAD(P)H oxidase (Nox) subunit 
1 (Nox1), Nox2 and interleukin-1β (IL-1β) were ana-
lyzed by quantitative RT-PCR as described previously 
[26]. Frozen aortic sections were stained with VCAM-1 
as described previously [26]. In brief, frozen aortic sec-
tions were fixed with cold acetone, and endogenous 
peroxidases were inactivated with 3% H2O2 in Tris-
buffered saline. Sections were then incubated with a 
protein blocking agent and a biotin-avidin blocking 
kit (Vector Laboratories). Following which, aortic sec-
tions were incubated with VCAM-1 primary antibody 
(1:100) overnight at 4  °C. Biotinylated anti-rat immu-
noglobulin (1:200; Vector Laboratories) was then added 
for 30 min, followed by horseradish peroxidase–conju-
gated streptavidin, diluted 1:500 (Dako), and incubated 
for 30  min in 3,3′-diaminobenzidine tetrahydrochlo-
ride (Sigma-Aldrich) with hematoxylin counterstain. 
Images were visualized under light microscopy and 
quantitated using Image Pro Plus. Three to five sections 
were assessed per mouse and averaged to obtain a sin-
gle value per mouse, and seven to nine mice were ana-
lyzed per group.
Systemic oxidative stress and aortic superoxide 
measurements
Derivatives of reactive oxygen metabolites (dROMs) 
were measured in plasma as an indication of oxidative 
stress using the FRAS-4 system as described previously 
[26, 30]. In addition, urinary 8-isoprostanes, a marker 
for lipid peroxidation, was measured using an ELISA kit 
from Oxford Biomedical Research as per manufacturer’s 
instructions. Superoxide content in frozen aortic sections 
was measured using dihydroethidium (DHE; 10 μmol/L) 
staining and imaged using a Zeiss 510 Meta confocal 
microscope equipped with a krypton/argon laser (excita-
tion 488 and emission 543  nm) as previously described 
by our group [31].
Cell culture
Human aortic endothelial cells (HAECs) and HAECs iso-
lated from a diabetic patient was purchased from Lonza 
Clonetics (CC-2919) and maintained in EGM-2 media 
(Lonza) supplemented with 10% FBS at 37 °C in 5% CO2. 
Experiments were performed on cells from passages 3–9. 
Upon 85% confluency, HAECs were treated with dh404 
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(25–100  nM) for a period of 24  h before experiments 
were performed.
RNA extraction and RT‑PCR of human aortic endothelial 
cells
Dh404-treated normal and diabetic HAECs were stimu-
lated with TNF-α (1  ng/ml) for 2  h. Following which, 
cells were washed twice with ice-cold PBS and lysed 
with RNA lysis buffer containing DNAse enzyme. After 
an incubation period of 7  min at room temperature 
with gentle agitation, a stop solution was added and 
DNAase-treated RNA was collected and its concentra-
tion was determined using the nanodrop spectropho-
tometer at 260 and 280 nm. Following which, DNA-free 
RNA (3  µg) was reverse-transcribed into cDNA using 
the Superscript First Strand System. 50 ng/µl of random 
primers were first added to RNA samples and incubated 
at 70 °C for 5 min, followed by immediate placement on 
ice. Meanwhile, a master mix was made from 4 μL of 5X 
first strand buffer, 2 μL of 10 mM dNTPs, 2 μL of 0.1 M 
dithiothreitol, 0.1 μL of RNase inhibitor (Promega; 20 U/
μL) and 1 μL of M-MuLV Reverse Transcriptase (200 U/
μL). The master mix was then added to the RNA mixture 
and incubated at room temperature (25  °C) for 10  min 
and subsequently incubated at 37  °C for 60  min and at 
70  °C for 10  min to complete the reverse transcription. 
The mixture was then pulse centrifuged to pellet any con-
densation and the cDNA was then stored at −20 °C until 
further use.
Western blotting
HAECs were washed twice with PBS and protein was 
isolated using RIPA buffer as described previously [32]. 
Protein concentration was determined using the BCA 
protein kit. Protein lysates, containing equal amounts 
of protein, were electrophoresed on a TGX Precast gel 
(Bio-Rad). On completion, the gel was activated imme-
diately and visualized on the BioRad imaging system for 
the detection and quantification of total protein using 
the Image Lab software. Proteins were then transferred 
to a polyvinylidene difluoride membrane using the trans-
blot turbo transfer system (BioRad). Membranes were 
then blocked with 5% skim milk in TBS at room temper-
ature for 1  h and then incubated with rabbit polyclonal 
VCAM-1 at 1:1000 dilution overnight at 4  °C. Pierce 
ImmunoPure Goat anti-rabbit IgG, peroxidase conju-
gated, was used as the secondary antibody for 1  h at 
room temperature and finally, proteins were visualized 
using the ECL Advance Western Blotting detection kit. 
Signals were quantitated by densitometry using Image 
Lab (Bio-Rad). Data are expressed relative to total protein 
and three independent experiments were analysed.
In vitro leukocyte‑adhesion assays
Monocyte–endothelial interactions were determined 
by performing in  vitro static cell adhesion assays as 
described previously [33]. Briefly, normal and diabetic 
HAECs were treated with TNF-α (1  ng/ml; 4  h) in the 
presence or absence of dh404 (24  h pre-treatment). 
In the meantime, human monocytic THP-1 cells were 
labeled with the CellVue Burgundy fluorescent labeling 
kit (Affymetrix) as per the manufacturer’s instructions 
and incubated with treated HAECs for 20 min at 37  °C. 
Thereafter, HAECs were washed twice with phosphate-
buffered saline, fixed with 10% NBF and plates were 
scanned using an Odyssey infra-red scanner. Fluores-
cence intensity (700  nm) of adherent THP-1 cells was 
quantified using Odyssey software.
Determination of reactive oxygen species levels
Dh404-treated control and diabetic HAECs were incu-
bated in phosphate buffered saline (PBS; with Ca2+/
Mg2+) containing Dichloro-fluorescein diacetate 
(DCFDA; 5 µM), an intracellular probe to detect reactive 
oxygen species (ROS) [34] for 40  min at 37  °C. Follow-
ing which, the cells were washed with PBS and incubated 
with PBS alone (control) or TNF-α (2 ng/ml) and placed 
into the Omega Fluorstar reader for fluorescence detec-
tion at 485 nm excitation and 530 nm emission. For L-012 
assays, a chemiluminescent probe to detect superoxide 
[35], dh404-treated control and diabetic HAECs were 
incubated with Krebs buffer containing L-012 (20 μM) in 
the presence and absence of TNF-α (2 ng/ml) and placed 
in a luminometer to detect L-012 enhanced chemilumi-
nescence for 1  h. Background readings were subtracted 
and relative chemiluminescence was quantified at 30 and 
60  min. Amplex red for the quantification of hydrogen 
peroxide [36] was determined in dh404-treated control 
and diabetic HAECs using the Amplex Red Hydrogen 
Peroxide/Peroxidase Assay Kit (Molecular Probes) as per 
the manufacturer’s instructions.
Statistical analysis
All data are expressed as mean ± standard error of mean 
(SEM). Comparison between groups were analysed by 
performing a two-way ANOVA with Tukey’s multiple 
comparison post hoc test. For vascular reactivity stud-
ies, a one-way ANOVA with Tukey’s multiple com-
parison post hoc test of the Rmax and EC50 values were 
performed. All statistical analyses were performed using 
GraphPad Prism version 6.0 (GraphPad Software, La 
Jolla, CA, USA). A P value <0.05 was considered statisti-
cally significant. Data and statistical analysis comply with 
the recommendations on experimental design and analy-
sis in pharmacology [37].
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Results
Body weight and metabolic parameters in WT and Akita 
mice
The body weight and metabolic parameters at the end 
point of the study of diabetic Akita mice and their WT 
counterparts treated with either vehicle or dh404 are 
depicted in Table  1. Akita mice displayed significantly 
lower body weights as compared to WT mice (p < 0.0001; 
Table  1). Treatment with dh404 did not affect the body 
weights in both WT and Akita mice when compared with 
vehicle controls (Table  1). Akita mice had significantly 
increased blood glucose and HbA1c levels as compared 
to WT mice, which was not altered with dh404 treatment 
(Table 1; p < 0.0001). Furthermore, the total cholesterol, 
triglycerides, HDL, and LDL levels were not significantly 
different between each group (Table  1). Overall, these 
findings indicate that treatment with dh404 did not alter 
the glucose and lipid parameters in WT and Akita mice.
Dh404 improves vascular function and oxidative stress 
in diabetic Akita mice
Endothelial function in the diabetic vasculature is mark-
edly impaired due to increases in oxidative stress and 
inflammation. Therefore, we investigated if the Nrf2 acti-
vator dh404 can improve endothelial dysfunction in the 
diabetic milieu by measuring vascular contractility in 
aortic rings isolated from WT and Akita mice. Impor-
tantly, Akita aortas exhibited significantly enhanced 
contraction to PE as compared to the WT aortas, which 
indicates that there is diminished inherent vasodilator 
capacity possibly due to lowered NO levels to counteract 
the PE-constricting effect (Fig.  1a; P  <  0.001). Although 
dh404 had no effect on WT aortas, dh404 was able to sig-
nificantly reduce the enhanced PE contractility in Akita 
aortas (Fig. 1a; P < 0.05).
To confirm these findings, we added l-NAME, a NOS 
inhibitor, after a sub-minimal preconstriction with 
U46619, a thromboxane A2 analogue. l-NAME inhib-
its any endogenous eNOS-derived NO present in the 
system. l-NAME caused a further contraction in the WT 
aortas as compared to the vehicle-treated Akita group 
(Fig.  1b; P  <  0.05), which is indicative of significantly 
more NO bioavailability in the WT groups. Importantly, 
dh404 was able to restore the contraction in the Akita 
group back to the levels observed in their WT counter-
parts (Fig. 1b; P < 0.05).
Additionally, we measured systemic ROS levels using 
two distinct assays, namely the urinary 8-isoprostane 
assay and plasma dROMs analysis. Urine from Akita mice 
displayed significantly elevated 8-isoprostane levels com-
pared to WT mice urine (Fig. 1c; P < 0.001), which was 
significantly attenuated with dh404 treatment (Fig.  1c; 
P  <  0.05). Similarly, plasma from Akita mice showed 
increased dROMs levels compared to plasma from WT 
mice (Fig.  1d; P  <  0.05). Furthermore, dh404 treatment 
showed trends towards reduced plasma dROMs levels 
in both WT and Akita mice (Fig. 1d). Lastly, superoxide-
specific DHE staining of aortic vessels from Akita mice 
showed a 12-fold increase as compared to WT vessels 
(Fig. 1e; P < 0.001). Whilst DH404 treatment had mini-
mal effect on superoxide-specific staining in WT vessels, 
it significantly reduced aortic superoxide levels in Akita 
vessels (Fig.  1e; P  <  0.01). Representative DHE stained 
vessels in the pressence and absence of Tempol are 
shown in Additional file 1: Figure S1
Dh404 reduces pro‑inflammatory and pro‑oxidative 
markers in the diabetic Akita macrovasculature
Inflammation and oxidative stress are major contributors 
towards the development of diabetes-associated endothe-
lial dysfunction. Thus, we investigated the effect of dh404 
on aortic gene expression levels of the pro-inflammatory 
markers, VCAM-1, ICAM-1, the p65 subunit of NF-κB 
and interleukin 1β (IL-1β), as well as the gene expression 
of the pro-oxidant enzyme Nox1 and Nox2. As expected, 
gene expression levels of these pro-inflammatory and 
pro-oxidant markers were elevated in diabetic Akita aor-
tas as compared to WT aortas (Fig.  2a–f). dh404 had 
Table 1 Impact of the Nrf2 activator dh404 on metabolic parameters in WT and Akita mice
Body weight, blood glucose, Hb1Ac, cholesterol, tryglycerides, HDL, LDL, and LH ratio were measured at 26 weeks of age. Data are presented as ±SEM. (**** P < 0.0001 
vs. WT + vehicle; n = 7/group)
WT + vehicle WT + dh404 Akita + vehicle Akita + dh404
Body weight (g) 32.3 ± 1.1 30.9 ± 1.1 21.5 ± 0.6**** 21.9 ± 0.6****
Blood glucose (mmol/L) 12.9 ± 1.0 11.6 ± 1.2 40.5 ± 3.7**** 39.0 ± 4.1****
HbA1c (%) 4.5 ± 0.1 4.9 ± 0.1 13.0 ± 0.3**** 12.0 ± 0.7****
Cholesterol (mmol/L) 1.8 ± 0.1 1.9 ± 0.1 1.7 ± 0.1 1.8 ± 0.2
Triglycerides (mmol/L) 0.6 ± 0.1 0.2 ± 0.1 0.9 ± 0.5 1.0 ± 0.3
HDL (mmol/L) 1.4 ± 0.1 1.5 ± 0.1 1.0 ± 0.1 1.1 ± 0.1
LDL (mmol/L) 0.2 ± 0.1 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1
LH ratio 0.2 ± 0.1 0.3 ± 0.1 0.7 ± 0.3 0.6 ± 0.2
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minimal effect on the expression of these genes in WT 
aortas. However, dh404 caused a significant reduction 
in pro-inflammatory and pro-oxidant gene expression in 
diabetic Akita aortas (Fig.  2a–f). This was further con-
firmed by investigating aortic VCAM-1 protein expres-
sion by immunohistochemistry. VCAM-1 expression 
was significantly increased in Akita aortas compared to 
WT aortas (Fig. 2g; P < 0.05). Dh404 reduced VCAM-1 
protein expression in Akita aortas back to the levels 
observed in WT aortas (Fig. 2g; P < 0.01).
Collectively, these data demonstrate that Nrf2 activa-
tion by dh404 improves vascular function by enhancing 
vasodilation in diabetic Akita vessels and this is associ-
ated with reductions in vascular oxidative stress and 
inflammation.
DH404 reduces oxidative stress parameters 
and upregulates antioxidant genes in diabetic settings
To specifically investigate the effects of Nrf2 activation of 
dh404 on endothelial cells, and to gain further mechanis-
tic insight, we examined the effect of dh404 on oxidative 
stress parameters in control and diabetic HAECs. Firstly, 
to confirm that dh404 is acting via the Nrf2 pathway, 
we investigated the effect of dh404 treatment on down-
stream Nrf2 antioxidant responsive genes, in particular 
HO-1 and NQO1. The basal expression of both HO-1 and 
NQO1 genes were similar in control and diabetic HAECs 
(Fig.  3a, b). After treatment with dh404 (25–50  nM), 
there was a significant dose-dependent increase in HO-1 
gene expression in both control and diabetic HAECs by 
~20 and ~25 fold respectively (Fig. 3a; P < 0.001). Simi-
larly, the expression of NQO1 was significantly increased 
following treatment with both doses in diabetic HAECs 
by ~2.5 fold as compared to their control (Fig.  3b; 
P < 0.01). Trends toward increased NQO1 gene expres-
sion was also observed in control HAECs after dh404 
treatment (Fig. 3b). Next we measured hydrogen perox-
ide levels using two independent ROS assays (DCFDA 
and the Amplex Red assay). Basal hydrogen peroxide 
levels were elevated in diabetic HAECs as compared to 
control HAECs, as revealed by the DCFDA and Amplex 
Red assays (Fig.  3c–f). Furthermore, there appeared 
to be a dose dependent decrease in hydrogen perox-





























Fig. 1 The Nrf2 activator dh404 improves vascular function in vivo. a Cumulative concentration–response curves to PE (0.001–100 µmol) and b 
contraction to l-NAME (100 µmol) was measured. *P < 0.05, ***P < 0.001 and ****P < 0.0001 versus WT + vehicle. #P < 0.05 versus Akita + vehicle. 
c Urinary 8-isoprostane (ng/24 h) and d plasma dROMs were measured. e Quantification of superoxide detection by DHE fluorescence imaging 
in aortas of WT and Akita mice treated with vehicle or Dh404 (3 mg/kg). *P < 0.05 and ***P < 0.001 as indicated. #P < 0.05 and #P < 0.01 versus 
WT + vehicle. Data are presented as ±SEM. N = 4–8 per group
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became significant at the higher dose of 50 nM (Fig. 3c, 
e). A trend toward a decrease was noted in control cells 
probed with DCFDA in Fig.  3c. Treatment with TNF-α 
had a marginal effect on hydrogen peroxide levels, whilst 
co-treatment with dh404 showed trends towards a reduc-
tion, particularly in the diabetic setting (Fig.  3d, f ). We 
also investigated the effect of dh404 on superoxide lev-
els in control and diabetic cells after TNFα treatment in 
Additional file 2: Figure S2A. There was a dose dependent 
decrease in superoxide levels in control cells which was 
significant at the higher dose of 50 nM. Trends towards 
a decrease were noted in the diabetic cells at both con-
centrations of dh404. In general, these data highlight 
the protective antioxidant features of Nrf2 activation by 
dh404 through the elevation in antioxidant genes and the 
suppression of oxidative stress markers such as superox-
ide and hydrogen peroxide.
Dh404 attenuates pro‑inflammatory genes and leukocyte–
endothelial interactions in vitro
Next, we examined the anti-inflammatory potential of 
dh404 in suppressing pro-inflammatory genes in con-
trol and diabetic HAECs. In particular, we investigated 
VCAM-1, an important pro-inflammatory marker that 
has been implicated in endothelial dysfunction and 
early stages of atherogenesis. The basal expression level 
of VCAM-1 is significantly elevated in diabetic HAECs 
by fivefold as compared to control HAECs (Additional 
file  2: Figure S2B). Upon TNF-α treatment, both con-
trol and diabetic HAECs showed significant increases in 
VCAM-1 expression. However, diabetic HAECs demon-
strated a ~3 fold increase in VCAM-1 gene expression 
as compared to control HAECs (Fig.  4a; P  <  0.0001). 
Importantly, VCAM-1 gene expression was signifi-






Akita vehicle Akita dh404
WT dh404 negative
Fig. 2 The Nrf2 activator dh404 reduces pro-inflammatory and pro-oxidative markers in diabetic Akita mice. mRNA expression levels of a VCAM-1, 
b ICAM-1, c p65 Rel A subunit of NF-κB, d IL-1β, e Nox1 and f Nox2 determined by qRT-PCR and expressed as fold induction relative to vehicle 
controls in WT mice. *P < 0.05, **P < 0.01 and ***P < 0.001 as indicated. #P < 0.05, ##P < 0.01 and ###P < 0.001 versus Akita + vehicle. g Representa-
tive images and quantification (right panel) of VCAM-1 immunostaining in aortas of WT and Akita KO mice treated with vehicle or dh404. *P < 0.05 
versus WT + vehicle group and ##P < 0.01 versus Akita + vehicle group. Data are presented as ±SEM. N = 6–8 per group
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both 25 and 50 nM in diabetic (Fig. 4a; P < 0.001) and 
control HAECs (Fig.  4a; P  <  0.05). Given the signifi-
cant increase in VCAM-1 gene expression, which was 
reduced with dh404, we investigated the effect of Nrf2 
activation on VCAM-1 protein levels in vitro. A signifi-
cant increase in VCAM-1 protein levels was observed in 
control and diabetic HAECs following TNF-α treatment 
as compared to untreated cells (Fig.  4b, c; P  <  0.001). 
This increase was more pronounced in diabetic HAECs 
(Fig. 4b, c; P < 0.05). Treatment with dh404 significantly 
reduced VCAM-1 protein levels in both control and dia-
betic HAECs (Fig. 4b, c; P < 0.001). Next we evaluated 
the gene expression of the p65 subunit of NF-κB which 
is upstream of VCAM-1 induction. The expression of 
p65 was significantly increased in diabetic HAECs by 
up to ~2 fold compared to control HAECs following 
treatment with TNF-α (Fig. 4d; P  <  0.01). Importantly, 
treatment with dh404 at 25 nM significantly suppressed 
p65 gene expression in diabetic HAECs back to the level 
observed in control HAECs (Fig. 4d; P < 0.01). Neither 
TNFα nor dh404 had any significant effect in control 
HAECs. 
Furthermore, in unstimulated conditions, we observed 
that diabetic HAECs exhibited significantly more adhe-
sion of fluorescently labelled monocytic THP-1 cells 
as compared to control HAECs by ~2 fold (Fig.  4e, f; 
P < 0.05). Addition of TNF-α induced a robust increase 
of THP-1 adhesion to both control and diabetic HAECs 
with significantly more attachment to the diabetic 
cells compared with controls (Fig.  4e, f; P  <  0.05 and 
P < 0.001). Importantly, Nrf2 activation by dh404 signifi-
cantly attenuated the leukocyte–endothelial interaction 
in both cell types back to levels observed in unstimu-
lated conditions (Fig. 4e, f ). In summary, these data sug-
gest that dh404 transcriptionally regulates inflammatory 
processes, such as leukocyte–endothelial interactions in 
Fig. 3 The effects of the Nrf2 activator dh404 on oxidative stress markers. Treatment with dh404 resulted in increased gene expression levels of 
HO-1 (a) and NQO1 (b). Dh404 treatment also resulted in attenuation of oxidative stress markers in basal and TNF-α treated control and diabetic 
HAECs. Oxidative stress markers are measured using DCFDA (c and d) and Amplex red (e and f) assays. Gene expression is relative to control HAECs. 
Data are presented as ±SEM. *P < 0.05, **P < 0.01, ***P < 0.001 and **** P < 0.0001 as indicated. #P < 0.05 versus diabetic HAECs. A.U: arbitrary units. 
N = 6–8 per group
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HAECs, in particular, by inhibiting the expression of p65 
and its downstream mediator, VCAM-1.
Discussion
Oxidative stress and inflammation have been inter-
linked as the underlying etiology in the pathogenesis of 
diabetes-associated endothelial dysfunction [38]. Strat-
egies to ameliorate both oxidative stress and inflamma-
tion may be beneficial in improving diabetes-associated 
endothelial dysfunction. In the current study, we dem-
onstrate that a potent activator of Nrf2, the synthetic 
compound dh404, improved endothelial dysfunction in 
a diabetic mouse model in vivo and attenuated oxidative 
stress and inflammatory markers in the setting of diabe-
tes in  vitro. Specifically, our findings showed that com-
promised endothelial function as defined by enhanced 
phenylephrine contractility, was improved after treat-
ment with dh404 in a diabetic mouse model. Addition-
ally, a range of pro-inflammatory mediators and oxidative 
stressors were lessened in response to dh404 treatment 
in the diabetic vasculature. Furthermore, the increased 
oxidative stress and pro-inflammatory markers detected 
in cultured endothelial cells from diabetic patients were 
attenuated by dh404 treatment. Importantly, the reduc-
tion in oxidative stress and pro-inflammatory mediators 
was associated with decreased adhesion of monocytes 
to endothelial cells in vitro. Collectively, our study shows 
that treatment with the Nrf2 activator, dh404, confers 
protection against diabetic endothelial dysfunction.
A characteristic phenomenon of vascular endothelial 
dysfunction is a deficiency in bioavailable vasodilators in 
particular nitric oxide (NO), which is reflected by hyper-
sensitization to PE-induced vasoconstriction. We dem-
onstrated that in comparison to aortic vessels isolated 
from WT mice, enhanced contraction to PE occurred in 
vessels from Akita mice, indicating that endogenous NO 
bioavailability is reduced in diabetic Akita vessels. These 
observations corroborate data from previous studies that 
show increased sensitivity to PE in vessels isolated from 
db/db and Akita diabetic mice [39, 40]. To confirm our 
hypothesis that endogenous NO bioavailability is com-










Control DH404 (25nM) DH404 (50nM)TNF-α

















Fig. 4 The Nrf2 activator dh404 inhibits pro-inflammatory markers and leukocyte–endothelial interactions in vitro. a VCAM-1 and d p65 gene 
expression is shown here. Gene expression is relative to control HAECs. b Representative VCAM-1 Western Blot and c quantification based on n = 3 
blots. VCAM-1 is expressed based on loading protein for each sample and quantified relative to control HAECs. e Representative images and f 
quantification of adherent human THP-1 monocytic cells to control and diabetic HAECs treated with TNF-α and dh404. Data are presented as ±SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 versus respective control treatments. #P < 0.05, ##P < 0.01, ###P < 0.001 and ####P < 0.0001 
versus respective TNF-α treated control and diabetic HAECs. N = 3–5 per group
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Since l-NAME inhibits eNOS function, further endog-
enous NO bioavailability is compromised such that the 
observed contraction induced by l-NAME is a reflection 
of the amount of endogenous NO present. Akita mice 
exhibited lower NO levels reflected by less LNAME-
induced contraction. Our study shows that Dh404 treat-
ment blunts PE- and l-NAME-induced contraction, 
indicating improved endothelial function by dh404 in 
diabetic aortas, which is in agreement with the study by 
Aminzadeh et  al. [41] which demonstrated that dh404 
improved CKD-induced endothelial dysfunction in rats 
associated with heightened level of oxidative stress.
Mechanistically, our results with dh404 showing an 
increase in Nrf2-responsive downstream genes as well as 
reductions in oxidative stress in a diabetic milieu, are in 
agreement with the known action of dh404 to act as an 
Nrf2 activator. Indeed, previous studies using adenovi-
rus mediated overexpression of Nrf2 in endothelial cells 
resulted in marked upregulation of antioxidant respon-
sive element (ARE)-driven genes in particular HO-1 and 
NQO1, protection against oxidative-stress mediated 
cytotoxicity and suppression of the inflammatory adhe-
sion molecules, monocyte chemotactic protein-1 (MCP-
1) and VCAM-1 [9, 42]. On the other hand, Nrf2 gene 
silencing demonstrated increased NF-κB activity and 
pro-inflammatory gene expression in cultured endothe-
lial cells exposed to high glucose conditions [43]. Fur-
thermore, the vascular endothelium of Nrf2 knockout 
mice displays a heightened pro-inflammatory and athero-
genic state compared to wild-type mice [43]. Therefore, 
dh404 in its capacity to act as an AIM, has demonstrated 
improved endothelial dysfunction in this study via its 
ability to modulate anti-oxidant and pro-inflammatory 
pathways. Additionally, we demonstrate that dh404 
affects pro-oxidant pathways since we show that the 
expression of prominent Nox family members is attenu-
ated by dh404 in Akita vessels.
Endothelial oxidative processes are directly implicated 
in pathogenic changes in the vasculature which includes 
vascular remodelling and inflammation, particularly 
through the induction of inflammatory molecules. The 
role of VCAM-1, an important pro-atherosclerotic cel-
lular adhesion molecule, has been shown to be regulated 
by the Nrf2 signaling pathway. Nrf2 negatively regulates 
VCAM-1 in the atheroprotected region of the aorta via 
modulating the p38-MAPK pathway [3]. Sulforaphane, 
a known Nrf2 activator, downregulates the expression of 
VCAM-1 in aortas of mice fed a high fat diet, a known 
model of type 2 diabetes. This upregulation of Nrf2 
activity was associated with overall protection against 
structural vascular changes induced in the diabetic envi-
ronment [15]. Our results are in alignment with these 
studies as we demonstrate a marked reduction in gene 
and protein expression of VCAM-1 after dh404 treat-
ment in both our in  vitro and in  vivo diabetic models. 
This was associated with a decreased expression of the 
p65 subunit of NF-kB, an inflammatory transcriptional 
modulator. Furthermore, our study shows for the first 
time in a diabetic setting that upregulation of Nrf2 activ-
ity and subsequent downstream regulation of VCAM-1 
is associated with less adhesion of circulating monocytes 
to endothelial cells in  vitro, which suggests that target-
ing the Nrf2 pathway is beneficial in limiting leukocyte 
recruitment, a critical early step in atherogenesis. Our 
study is also consistent with earlier observations show-
ing that AIMs such as RTA 403 or CDDO-Im suppress 
leukocyte adhesion in mouse retina [44]. However, it is 
imperative to note that the role of Nrf2 remains contro-
versial in the development of cardiovascular diseases, 
particularly in atherogenic settings where Nrf2 has been 
shown to have opposing influences. Increases in Nrf2 
expression have been reported to have an anti-inflamma-
tory effect in athero-susceptible vascular regions, which 
is mediated mainly through its regulation of HO-1 [45, 
46]. However, despite its anti-oxidative and anti-inflam-
matory actions, Nrf2 knockout mice on an ApoE−/− 
background exhibited protection against atherosclerosis. 
This was shown to be due to the role that Nrf2 plays in 
CD36 expression and ox-LDL uptake into macrophages, 
thereby promoting macrophage infiltration and foam cell 
formation in the vascular endothelium [47]. Due to the 
complexity of Nrf2 regulation in cardiovascular diseases 
it is apparent that therapeutic modulation of Nrf2 must 
consider the delicate balance between pro-inflammatory 
and anti-inflammatory actions of Nrf2. Indeed, as we 
have previously shown for Nrf2 activation, a window of 
atheroprotection exists above which the beneficial pro-
tective effects are lost [26], suggesting that careful dosage 
considerations are needed. Indeed, too much Nrf2 acti-
vation could disturb the homeostatic balance by blunt-
ing important ROS-based signalling with detrimental 
consequences. A further complexity arises when athero-
sclerosis is assessed in Nrf2−/− mice crossed with LDL 
R−/− mice, where in this instance lack of Nrf2 promoted 
atherogenesis through the increased formation of foam 
cells [48], suggesting that local interactions of Nrf2 may 
affect outcomes.
Finally, it is noteworthy that we observed significant 
differences between HAECs derived from diabetic ver-
sus non-diabetic patients with respect to basal levels of 
oxidative stress, pro-inflammatory mediators and pro-
oxidant enzymes. Given that HAECs were derived from 
a diabetic patient yet cultured in low glucose, it is tempt-
ing to speculate that basal levels had become modified 
in favour of a more activated state whilst exposed to the 
diabetic environment within the patient, suggesting a 
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memory effect. This is consistent with current theories 
where glucose-driven epigenetic modifications alter gene 
expression [49, 50]. This may also account for the legacy 
effect seen in clinical trials of intense glucose lowering 
[51]. However, one caveat needs to be kept in mind that 
the HAECs are derived from one control and one dia-
betic patient respectively and patient variability may play 
a significant factor.
Conclusion
In conclusion, our study shows that upregulation of Nrf2 
activity through pharmacological intervention is ben-
eficial in ameliorating endothelial dysfunction in diabetic 
vascular disease settings. Given the critical role of main-
taining a functional endothelium, our strategy has impli-
cations for the protection against diabetes-associated 
atherosclerosis, a diabetic complication with significant 
health burden. Mechanistically, we now show that Nrf2 
upregulation with dh404 is associated with anti-inflam-
matory and anti-oxidative actions within diabetic aortic 
vessels and in human aortic endothelial cells. This trans-
lated into improved vascular contractility and reduced 
endothelial–leukocyte interactions in the diabetic milieu 
(Fig.  5). Overall, we speculate that Nrf2 activation rep-
resents a novel therapeutic strategy to improve diabe-
tes-associated endothelial function which in turn may 
protect against diabetes-associated atherosclerosis. With 
the current greater understanding of which patients are 
likely to benefit from this class of drug based on follow-
up analysis of the BEACON trial, which helped identify 
an important set of at-risk patients [25], further pre-
clinical research into the cardiovascular outcomes of this 
drug class, such as this study, and that of other novel Nrf2 
activators is warranted.
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Fig. 5 Graphical representation of the role of dh404 in limiting diabetes-associated endothelial dysfunction. Hyperglycemia increases ROS genera-
tion, lowers endothelial derived NO and upregulates inflammatory pathways, in particular leukocyte–endothelial interactions which are mediated 
by VCAM-1. Consequently there is a reduction in vascular function, a phenomenon described as diabetes-associated endothelial dysfunction. 
Dh404 is an Nrf2 activator, which disrupts the Nrf2/Keap-1 interaction, thereby allowing Nrf2 to translocate to the nucleus where it modulates 
antioxidant and pro-inflammatory gene expression. This study demonstrates that the Nrf2 activator, dh404, inhibits ROS production, lessens 
pro-inflammatory mediators and improves vascular function. In particular, we show that dh404 downregulates VCAM-1 which is associated with 
reduced leukocyte–endothelial interactions. Black arrows represent stimulation; red dotted lines represent inhibition
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